Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated subjects with locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Pancreatic Cancer
DRUG: TH-302|DRUG: Nab-paclitaxel|DRUG: Gemcitabine
Number of Subjects Experiencing Dose Limiting Toxicity (DLT), Up to Day 28 of Cycle 1
Progression Free Survival (PFS) Time, Time from enrollment to progressive disease (PD) or occurrence of death due to any cause within 120 days of either first administration of study drug or the last tumor assessment|Percentage of Subjects With Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) Criteria, Every 8 weeks from Day 1 of Cycle 1 until disease progression or within 1 week after discontinuation of study treatment|Duration of Overall Response According to RECIST Version 1.1 Criteria, Every 8 weeks from Day 1 of Cycle 1 until disease progression or within 1 week after discontinuation of study treatment|Percentage of Subjects With Disease Control According to RECIST Version 1.1 Criteria, Every 8 weeks from Day 1 of Cycle 1 until disease progression or within 1 week after discontinuation of study treatment|Tumor Metabolic Response Assessed by Positron Emission Tomography (PET) Scans According to European Organization for Research and Treatment of Cancer (EORTC) Criteria, Baseline and 8 weeks after Day 1 of Cycle 1|Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Baseline up to Day 30 after the last dose of study treatment
This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated subjects with locally advanced unresectable or metastatic pancreatic adenocarcinoma.